Franco S.
- Country
- Italy
- Department
- IT10009, UOC CEMAD (Centro malattie apparato Digerente)
Research Overview
- Phase 2 Study of LY4268989 Co-administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
- Phase 2 Randomized Study of LY4395089 Combined with Mirikizumab Versus Mirikizumab Alone in Adults with Moderately to Severely Active Crohn’s Disease
- Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of Oral MH002 (10 000 vs 40 000 million CFU) in Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled with 5‑ASA
Data & Insights
Has run more than one trial at 149 of 226 partner sites.
Specializations
Inflammatory Bowel Disease Research
Specializes in investigating therapeutic approaches for fistulizing perianal Crohn's Disease, with particular emphasis on advanced biological treatments.
- Complex Perianal Fistulas
- Crohn's Disease Management
- Biological Therapy Assessment
Focuses on evaluating innovative therapeutic options for patients with challenging manifestations of inflammatory bowel conditions.
Gastrointestinal Therapeutics
Conducts research in targeted immunological treatments for complex gastrointestinal disorders, particularly focusing on novel therapeutic agents.
- Advanced Therapeutic Approaches
- Clinical Efficacy Studies
- Treatment Response Assessment
Examines cutting-edge interventions for complex gastrointestinal conditions requiring specialized therapeutic approaches.
Clinical Immunology
Investigates immune-mediated inflammatory conditions with a specific focus on gastrointestinal tract manifestations and therapeutic interventions.
- Immunological Response Patterns
- Therapeutic Safety Profiles
- Treatment Optimization Strategies
Explores the intersection of immunological mechanisms and gastrointestinal disease manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.